ÂÜÀòÂÒÂ×

Peter Dudek is an experienced professional in the biotechnology sector, currently serving as a Board Observer at Insamo since January 2024. Peter has held significant leadership roles at Merck, including President & Managing Partner of the MRL Ventures Fund since April 2018. Additionally, Peter is involved in various companies as a Board Director or Observer, including InduPro, Photys Therapeutics, Tallac Therapeutics, Mozart Therapeutics, Ambagon Therapeutics, and previously Caraway Therapeutics and Carisma Therapeutics. Peter holds a Doctor of Philosophy in Cell Biology from the University of Geneva and has pursued advanced studies at the University of Oxford, complemented by a Bachelor of Science (Hons) from The University of British Columbia and an Associate of Science from Capilano University.